AbbVie (ABBV) maintains long-term guidance for high single-digit revenue growth through the decade, with EPS growth outpacing sales via operating-margin expansion, via JPM Conference

AbbVie (ABBV) maintains long-term guidance for high single-digit revenue growth through the decade, with EPS growth outpacing sales via operating-margin expansion, via JPM Conference.

AbbVie is reaffirming its long-term revenue growth expectations, targeting high single-digit increases over the next decade. With projected EPS growth outpacing revenue through margin improvements, this guidance indicates confidence in operational efficiency that could help support the stock's performance amidst competitive pressures in the biotechnology sector.